RxDoctor Payments DataLook up a doctor →

Maya Srivastava, MD

Gastroenterology · Williamsville, NYNPI 1982615100

Payments from drug & device makers

$1,835,038in general payments, 2019–2025

Across 1,488 payments — averaging $1233.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$427K
  • Johnson & Johnson$339K
  • Regeneron Healthcare Solutions, Inc.$305K
  • Takeda Pharmaceuticals U.S.A., Inc.$296K
  • Janssen Scientific Affairs, LLC$216K
  • AbbVie$193K
  • plus $59K from 19 others

What the payments were for

  • Consulting fees$17,9011%
  • Speaking & faculty fees$1,423,01978%
  • Travel & lodging$361,72220%
  • Food & beverage$32,1872%
  • Education$2080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,835,038 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$11,947
Medicare patients
25
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab16$424,577
Skyrizi On-BodyRisankizumab-Rzaa11$237,983
CreonLipase/Protease/Amylase30$197,421
Humira(Cf) PenAdalimumab21$175,376
PentasaMesalamine17$35,836
Mesalamine25$25,771
MotegrityPrucalopride Succinate17$15,580
Mesalamine ErMesalamine41$15,167
LinzessLinaclotide15$13,169
Sucralfate13$2,309
Pantoprazole Sodium177$2,227
Ursodiol17$1,830
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$1,022
Lansoprazole43$668
Esomeprazole Magnesium33$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$339,068$424,57716 claims
AbbVieCreon, Linzess$193,142$210,59045 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$296,005$15,58017 claims
SandozLansoprazole$20$66843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →